Egeberg A, et al. - A total of 368 and 62 candidates receiving secukinumab and ixekizumab, respectively were estimated to evaluate the drug survival of secukinumab and ixekizumab in subjects with psoriasis in Denmark. They observed that 40.7% and 12.9% of secukinumab and ixekizumab-treated cases were bio-naive. They found discontinuation of therapy among 23.5% and 0.0% of bio-naive secukinumab- and ixekizumab-treated cases over 12 months. They noted lower drug survival for bio-naive and non-naive subjects for secukinumab as compared to ixekizumab. They reported lowest secukinumab drug survival for individuals who had earlier been treated with 2 or more biologics, followed by cases treated with secukinumab as their second-ever biologic during the maximum 3 years of follow-up.